Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.
Trial Parameters
Brief Summary
Pharmacokinetic and pharmacodynamic modeling (PKPD) is becoming an essential tool for optimizing pharmacotherapy. Building mechanistic models allows determining the relationship between the dose, concentration, pharmacological effect, and side effects in various populations. The growing resistance to drugs among bacteria is a challenge for medicine, and the progress in pharmacometrics enables us to make rational clinical decisions. A particular group of patients is children with differences in PK and PD of drugs. The lack of clinical studies often forces to extrapolate dosing based on the results obtained in adults. In intensive care units, up to 70-90% of drugs in children are used off-label. Drug agencies point to the importance of the population-based approach to data analysis, especially in infants and children. Under the project, work will focus on the PK and PD of antifungal drugs (fluconazole, isavuconazole, and anidulafungin) and antibiotics (cefotaxime and meropenem) in the pediatric and adult populations. The choice of topic is dictated by the growing need to create PKPD models of the drugs mentioned above in children. The hypothesis is the assumption that using a mathematical model will enable to describe the time course of the drug in the organism, the relationship between the effect and the dose of the medicine and its concentration in the plasma, and the influence of individual factors on the PKPD profile of a drug.
Eligibility Criteria
Inclusion Criteria: * Obtaining informed consent from the patient/parent of the patient * A bacterial and fungal infection that requires the use of at least one of the drugs listed based on clinical indications and the attending physician's decision. Exclusion Criteria: * Proven allergic reaction to medications used * No written consent * Contraindications in SmPC * Combination therapy with at least two antibacterial drugs and/or at least two antifungal drugs